Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRS-344 + ONC0055
- Development stage
- Unknown
- Lead developer
- Pieris Pharmaceuticals
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
PRS-344 + ONC0055 is an investigational combination therapy for solid tumors. PRS-344 (also known as S095012) is a bispecific fusion protein consisting of a PD-L1–targeting antibody and 4-1BB–targeting Anticalin proteins. Mechanistically, PRS-344/S095012 blocks the PD-1/PD-L1 immune checkpoint and simultaneously provides tumor-localized costimulation of 4-1BB (a T cell costimulatory receptor), thus enhancing antitumor immunity by potentiating T cell activation and cytokine release in a manner dependent on both PD-L1 expression and T cell receptor (TCR) engagement[3][4][9][13][18][22]. ONC0055, based on available information, is associated with Rapafusyn Pharmaceuticals and is described as a non-degrading molecular glue for solid tumors, but its detailed mechanism and structure are unclear[2]. The combination is intended to synergistically boost antitumor immunity by dual targeting, but no detailed data on ONC0055’s molecular target, mechanism, or published clinical data for the combination exists.
- Other names
- PRS-344/S095012 + ONC0055
02
Targets
TNFRSF9 (CD137 extracellular domain)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PRS-344 + ONC0055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRS-344 + ONC0055.